

Drug Enlistment Task Force

Name	Company
Peggy Fung (Sponsor)	GSK
Cheryl Ng (Lead)	AbbVie
Stephen Or	Bayer
Paul Wong	GSK
Kammy Leung	Janssen
Shadow Wan	Merck
Catherine Chao	MSD
Paul Chong	Roche
Solon Kao	Sanofi
Marco Lee	Takeda

Objective	To increase the transparency, and streamline the process of the drug enlistment system in HK and Macao	
Endpoint	Hong Kong	Macao
	<p>Streamline the process & Equity among clusters</p> <p>Identify opportunities to further streamline the process of drug enlistment to HA Drug Formulary:</p> <ol style="list-style-type: none"> 1) Relaxation of DTC quotas for DAC submission 2) To shorten the time of drug code creation after DAC approval 3) To align different DTC's pre-DAC meeting time so that pharma would not miss the DAC submission time <p>To address the inequity of drug access between clusters from patient perspective esp. after DAC approval to hospitals:</p> <ol style="list-style-type: none"> 4) To enable negative vetting for post-DAC DTC with the support of scientific evaluation summary from DAC 5) To allow the enlistment of SFIs directly as they do not incur budget impact 	<p>Formulary Expansion</p> <ol style="list-style-type: none"> 1) Support HA to build performance-based program (PBP) capability by speaker sharing and pilot program. Propose solutions for PBP in facilitate timely access to innovative treatments. 2) Explore the feasibility of accelerating phase 2b drug access in HA by managed entry agreement (MEA). 3) Seek more clarify from CPO for ultra expensive drug enlistment criteria in CCF and communicate to members
Future State	Accelerated and broader reimbursement which enable early affordable access to innovative medicines within 12 months in HA	Increase the transparency of drug enlistment with best practice sharing and some process improvement